Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

Completed · Phase 1

Conditions studied: Acute Renal Failure

In brief

OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte stimulating hormone (alpha-MSH) in patients with acute renal failure. II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute renal failure after renal transplantation. III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established ischemic acute renal failure. IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.

Key facts

Study ID

NCT00004496

Run by

University of Texas

People needed

45

Starts

1999-02-01

Expected to finish

2003-09-01

Last updated by the study team

2015-03-25

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas Southwestern Medical Center at Dallas — Dallas, Texas, United States
• Baylor University Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.